272 related articles for article (PubMed ID: 34272748)
21. Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).
Bağlan E; Kızıldağ Z; Çağlayan Ş; Çakmak F; Yener GO; Özdel S; Öztürk K; Makay B; Çakan M; Ayaz NA; Sözeri B; Ünsal ŞE; Bülbül M
Clin Rheumatol; 2023 Oct; 42(10):2855-2860. PubMed ID: 37378874
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study: Impact of consensus treatment plans on systemic therapy of pediatric morphea.
Do N; Ringold S; Sullivan E; Brandling-Bennett H
Pediatr Dermatol; 2020 Mar; 37(2):278-283. PubMed ID: 31967352
[TBL] [Abstract][Full Text] [Related]
23. Systemic involvement in localized scleroderma/morphea.
Gorkiewicz-Petkow A; Kalinska-Bienias A
Clin Dermatol; 2015; 33(5):556-62. PubMed ID: 26321403
[TBL] [Abstract][Full Text] [Related]
24. Localized scleroderma: a clinical study at a single center in Korea.
Noh JW; Kim J; Kim JW
Int J Rheum Dis; 2013 Aug; 16(4):437-41. PubMed ID: 23992265
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological study of 81 cases of localized and systemic scleroderma.
Succaria F; Kurban M; Kibbi AG; Abbas O
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e191-6. PubMed ID: 22620486
[TBL] [Abstract][Full Text] [Related]
26. [How I explore ... the skin functional involvement in scleroderma].
Hermanns-Lê T; Piérard-Franchimont C; Piérard GE; André B; De Roover C; Renwart L; Delvenne P
Rev Med Liege; 2013 Mar; 68(3):141-7. PubMed ID: 23614323
[TBL] [Abstract][Full Text] [Related]
27. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
McGaugh S; Kallis P; De Benedetto A; Thomas RM
Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
[TBL] [Abstract][Full Text] [Related]
28. Morphea and other localized forms of scleroderma.
Vasquez R; Sendejo C; Jacobe H
Curr Opin Rheumatol; 2012 Nov; 24(6):685-93. PubMed ID: 23018858
[TBL] [Abstract][Full Text] [Related]
29. Morphea: Current concepts.
Florez-Pollack S; Kunzler E; Jacobe HT
Clin Dermatol; 2018; 36(4):475-486. PubMed ID: 30047431
[TBL] [Abstract][Full Text] [Related]
30. Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review.
Martini G; Fadanelli G; Agazzi A; Vittadello F; Meneghel A; Zulian F
Autoimmun Rev; 2018 Jul; 17(7):727-734. PubMed ID: 29729451
[TBL] [Abstract][Full Text] [Related]
31. Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review.
Mansour M; Liy Wong C; Zulian F; Li S; Morishita K; Yeh EA; Stewart K; Laxer RM; Pope E
Pediatr Dermatol; 2018 Nov; 35(6):761-768. PubMed ID: 30187959
[TBL] [Abstract][Full Text] [Related]
32. MRI findings in deep and generalized morphea (localized scleroderma).
Horger M; Fierlbeck G; Kuemmerle-Deschner J; Tzaribachev N; Wehrmann M; Claussen CD; Fritz J
AJR Am J Roentgenol; 2008 Jan; 190(1):32-9. PubMed ID: 18094291
[TBL] [Abstract][Full Text] [Related]
33. [The clinical picture of morphea].
Wojas-Pelc A; Wielowieyska-Szybińska D
Przegl Lek; 2007; 64(6):438-41. PubMed ID: 18159855
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of morphea and lichen sclerosus and atrophicus in children.
Pope E; Laxer RM
Pediatr Clin North Am; 2014 Apr; 61(2):309-19. PubMed ID: 24636648
[TBL] [Abstract][Full Text] [Related]
35. Case study: periodic follow-up is necessary in morphea profunda to identify systemic evolution.
Melani L; Cardinali C; Giomi B; Schincaglia E; Caproni M; Fabbri P
Skinmed; 2005; 4(3):188-90. PubMed ID: 15891259
[TBL] [Abstract][Full Text] [Related]
36. Scleroderma and dentistry: Two case reports.
Dixit S; Kalkur C; Sattur AP; Bornstein MM; Melton F
J Med Case Rep; 2016 Oct; 10(1):297. PubMed ID: 27776552
[TBL] [Abstract][Full Text] [Related]
37. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
38. [Solitary morphea profunda: An unusual form of localized scleroderma in childhood. Case report].
de la Fuente-Laso P; González-García J; Castaño-Rivero A; Gonzalvo-Rodríguez P; Rodríguez-Díaz E; Vázquez-Osorio I
Arch Argent Pediatr; 2019 Apr; 117(2):e137-e141. PubMed ID: 30869492
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea.
García-Romero MT; Tollefson M; Pope E; Brandling-Bennett HA; Paller AS; Keimig E; Arkin L; Wanat KA; Humphrey SR; Werth VP; Oza V; Jacobe H; Fett N; Cordoro KM; Medina-Vera I; Chiu YE
JAMA Dermatol; 2023 Mar; 159(3):299-307. PubMed ID: 36753150
[TBL] [Abstract][Full Text] [Related]
40. Coexistence of morphea and systemic sclerosis.
Soma Y; Tamaki T; Kikuchi K; Abe M; Igarashi A; Takehara K; Ishibashi Y
Dermatology; 1993; 186(2):103-5. PubMed ID: 8428037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
